A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD
Abstract Management of apathy, depression and anxiety in Parkinson’s disease (PD) represents a challenge. Dopamine agonists have been suggested to be effective. This multicenter, randomized (1:1), double-blind study assessed the 6-month effect of rotigotine versus placebo on apathy, depression and a...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/34b6579169b943c7944a08d2e7aba062 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:34b6579169b943c7944a08d2e7aba062 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:34b6579169b943c7944a08d2e7aba0622021-12-02T12:42:30ZA randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD10.1038/s41531-020-00142-x2373-8057https://doaj.org/article/34b6579169b943c7944a08d2e7aba0622020-12-01T00:00:00Zhttps://doi.org/10.1038/s41531-020-00142-xhttps://doaj.org/toc/2373-8057Abstract Management of apathy, depression and anxiety in Parkinson’s disease (PD) represents a challenge. Dopamine agonists have been suggested to be effective. This multicenter, randomized (1:1), double-blind study assessed the 6-month effect of rotigotine versus placebo on apathy, depression and anxiety in de novo PD. The primary outcome was the change of apathy, measured with the LARS. The secondary outcomes were the change in depression and anxiety, measured with BDI-2 and STAI-trait and state. Forty-eight drug-naive PD patients were included. The primary outcome was not reached, with a surprisingly high placebo effect on apathy (60%). There was no significant difference in the change of depression at 6 months between rotigotine and placebo. Trait-anxiety was significantly improved by rotigotine compared to placebo (p = 0.04). Compared to placebo, low dose rotigotine significantly improved trait anxiety, but not apathy and depression. The major placebo effect on apathy points towards the importance of a multidisciplinary and tight follow-up in the management of neuropsychiatric symptoms.A. CastriotoS. ThoboisM. AnheimJ. L. QuesadaE. LhomméeH. KlingerA. BichonE. SchmittF. DurifJ. P. AzulayJ. L. HouetoN. LongatoC. PhilippsP. PelissierE. BroussolleE. MoroC. TranchantV. FraixP. Krackfor the Honeymoon study groupNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 6, Iss 1, Pp 1-6 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurology. Diseases of the nervous system RC346-429 A. Castrioto S. Thobois M. Anheim J. L. Quesada E. Lhommée H. Klinger A. Bichon E. Schmitt F. Durif J. P. Azulay J. L. Houeto N. Longato C. Philipps P. Pelissier E. Broussolle E. Moro C. Tranchant V. Fraix P. Krack for the Honeymoon study group A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD |
| description |
Abstract Management of apathy, depression and anxiety in Parkinson’s disease (PD) represents a challenge. Dopamine agonists have been suggested to be effective. This multicenter, randomized (1:1), double-blind study assessed the 6-month effect of rotigotine versus placebo on apathy, depression and anxiety in de novo PD. The primary outcome was the change of apathy, measured with the LARS. The secondary outcomes were the change in depression and anxiety, measured with BDI-2 and STAI-trait and state. Forty-eight drug-naive PD patients were included. The primary outcome was not reached, with a surprisingly high placebo effect on apathy (60%). There was no significant difference in the change of depression at 6 months between rotigotine and placebo. Trait-anxiety was significantly improved by rotigotine compared to placebo (p = 0.04). Compared to placebo, low dose rotigotine significantly improved trait anxiety, but not apathy and depression. The major placebo effect on apathy points towards the importance of a multidisciplinary and tight follow-up in the management of neuropsychiatric symptoms. |
| format |
article |
| author |
A. Castrioto S. Thobois M. Anheim J. L. Quesada E. Lhommée H. Klinger A. Bichon E. Schmitt F. Durif J. P. Azulay J. L. Houeto N. Longato C. Philipps P. Pelissier E. Broussolle E. Moro C. Tranchant V. Fraix P. Krack for the Honeymoon study group |
| author_facet |
A. Castrioto S. Thobois M. Anheim J. L. Quesada E. Lhommée H. Klinger A. Bichon E. Schmitt F. Durif J. P. Azulay J. L. Houeto N. Longato C. Philipps P. Pelissier E. Broussolle E. Moro C. Tranchant V. Fraix P. Krack for the Honeymoon study group |
| author_sort |
A. Castrioto |
| title |
A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD |
| title_short |
A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD |
| title_full |
A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD |
| title_fullStr |
A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD |
| title_full_unstemmed |
A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD |
| title_sort |
randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo pd |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/34b6579169b943c7944a08d2e7aba062 |
| work_keys_str_mv |
AT acastrioto arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT sthobois arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT manheim arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT jlquesada arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT elhommee arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT hklinger arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT abichon arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT eschmitt arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT fdurif arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT jpazulay arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT jlhoueto arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT nlongato arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT cphilipps arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT ppelissier arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT ebroussolle arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT emoro arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT ctranchant arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT vfraix arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT pkrack arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT forthehoneymoonstudygroup arandomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT acastrioto randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT sthobois randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT manheim randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT jlquesada randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT elhommee randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT hklinger randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT abichon randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT eschmitt randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT fdurif randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT jpazulay randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT jlhoueto randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT nlongato randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT cphilipps randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT ppelissier randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT ebroussolle randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT emoro randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT ctranchant randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT vfraix randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT pkrack randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd AT forthehoneymoonstudygroup randomizedcontrolleddoubleblindstudyofrotigotineonneuropsychiatricsymptomsindenovopd |
| _version_ |
1718393676678299648 |